Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal ...
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-α as first-line treatment for patients with metastatic renal-cell carcinoma.
Hosted on MSN11mon
Kidney cancer treatments and tumor biology can activate different immune-modifying processes in patientsthan those treated with sunitinib. In analyzing participants' blood and tumor samples, researchers found that treatment with avelumab and axitinib led to a greater change in T-cell repertoire but ...
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback